GA NCORP

Treatment Sites

Northside Hospital Cancer Institute

Northside Hospital Cancer Institute
Atlanta, Georgia

Northside Hospital Cancer Institute offers the best of both worlds: clinical excellence on par with academic-based programs, along with the personalized and attentive care typically associated with a community hospital. Northside, which has been offering cancer care services since 1978, is one of the largest and most respected providers of cancer care services in the Southeast.


  • The Blood & Marrow Transplant Program at Northside Hospital has ranked #1 in the United States for the third consecutive year, for having the best survival rates for matched related and unrelated donors (MUD) /allogeneic transplants.
  • More cases of breast cancer and gynecologic (cervical, ovarian and uterine) cancer are diagnosed and treated than at any other hospital in the Southeast.
  • More prostate cancer treatments are performed at Northside than at any other hospital in Atlanta
  • Fully accredited by the American College of Surgeons Commission on Cancer.
    Northside also received an Outstanding Achievement Award.

Our renowned program also consists of palliative care, cancer genetics, screenings, research, support and survivorship.

(404) 851-8000
www.northside.com

Treatment Sites


Primary Location

1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355 (p)
www.northside.com

driving directions

Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator: Stacey Brown - 404-780-7965


A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type: Non-Hodgkin Lymphoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma, Unknown Primary

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer
Study Coordinator: - 404-303-3355


Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type: Non-Hodgkin Lymphoma

CIBMTR Research Database
Cancer Type: Hematopoietic Malignancies, Solid Tumor
Study Coordinator: Stacey Brown - 404-780-7965


Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355


Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer, Unknown Primary
Study Coordinator: - 404-303-3355


National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor
Study Coordinator: - 404-303-3355


Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Cancer Type: Unknown Primary

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
Study Coordinator: - 404-303-3355


Understanding Heart Risks of People With HER2-Positive Breast Cancer That Has Spread
Cancer Type: Breast Cancer
Study Coordinator: - 404-303-3355